Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Investor Presentation (February 2026)
41 slides from Eris Lifesciences's investor presentation, Feb 20, 2026
Slide 1: Exchange filing cover letter for corporate presentation
Date: 20 February 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai – 400001 Bandra (E) Mumbai – 400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION REF: REGULATION 30 OF SEBI (LODR)
Slide 2: Corporate Presentation February 2026
CORPORATE PRESENTATION February 2026
Slide 3: Introduction; Domestic Branded Formulations; R&D; International Business
• Introduction • Domestic Branded Formulations • R&D, Technology & Manufacturing • International Business 2
Slide 4: Introduction to Eris
INTRODUCTION TO ERIS ▪ Domestic Branded Formulations ▪ Among the Top-20 Indian pharmacos in less than 20 years since inception; youngest company on the list ▪ Strong presence in Super-Specialty segment accounting for 80% of revenue ▪ Top-5 market position (by revenue) in Anti-Diabetes therapy with a
Slide 5: Leveraged acquisitions to enter dermatology, injectables & biologics
LEVERAGED ACQUISITIONS TO ENTER DERMATOLOGY, INJECTABLES & BIOLOGICS…. FY22 Revenue INR 195 cr; FY23 Revenue INR 280 cr; Revenue INR 50 cr 10% EBIDTA margin 37% EBIDTA margin 70% of Swiss 30 % Stake in Swiss Oaknet – entry into Derma Brands from Eris BioNxt Parenterals Ltd. Parenterals Derma (INR 65
Slide 6: Significant expansion in therapeutic & geographic footprints
…WITH A SIGNIFICANT EXPANSION IN THERAPEUTIC & GEOGRAPHIC FOOTPRINTS Geographies We now have manufacturing ops across 6 1 Expanded geographic reach from India to globally accredited/ compliant facilities USA Africa, Asia-Pacific, Latam and the deploying a diverse suite of technologies CIS/Middle Eas
Slide 7: All acquisitions integrated; margins expanded 400 bps since FY23
ALL ACQUISITIONS INTEGRATED; MARGINS EXPANDED 400 BPS SINCE FY23 REVENUE (INR CR) EBITDA (INR CR) PAT (INR CR) 1,200 36% 36% 37% 35% 36% 1,000 2,894 35% 406 800 34% 397 2,373 34% 380** 2,009 600 32% 33% 374 375 1,685 1,347 400 32% 31% 200 30% 485 537 675 1,017 847 0 29% FY22 FY23 FY24 FY25 9MFY26 FY
Slide 8: Entered an era of accelerated EPS growth over FY26-FY28
ENTERED AN ERA OF ACCELERATED EPS GROWTH OVER FY26-FY28 Last 4 years’ Investment Cycle Outlook – FY26 and Beyond FY 22 FY 25 A • Inflection point in EPS growth starting FY26, Assets* 921 ~5,400 6x driven by multiple factors • Growth and margin improvement in EPS 29.9 ~28 19% acquired businesses • De
Slide 9: Strategic investments in diabesity & injectables over next 2-3 quarters
3 QUARTERS STRATEGIC INVESTMENTS IN DIABESITY & INJECTABLES OVER NEXT 2-3 QUARTERS Market Opportunity Strategic investment • Capex outlay of Rs. 380-400 cr. over the RoW market opportunity Insulin capacity doubling 1 next 2-3 quarters in Insulins/ GLP-1 at Bhopal – Rs. 150 cr. • Will be funded throu
Slide 10: Debt reduction – reiterating guidance of <1.5x debt-to-EBITDA by Dec-26
DEBT REDUCTION – REITERATING GUIDANCE OF < 1.5x DEBT-TO-EBIDTA BY DEC-26 Debt-to-EBIDTA Ratio Debt-to-EBIDTA Ratio Debt Reduction guidance Plan shared at the start of FY26 Outlook at the end of Q2-FY26 • Net Debt to TTM EBIDTA ratio has significantly Outstanding Debt to Outstanding Debt to As On Dat
Slide 11: Domestic Branded Formulations
• Introduction • Domestic Branded Formulations • R&D, Technology & Manufacturing • International Business 10
Slide 12: Expanded domestic CVM/TAM by 77% during Apr-23 to Dec-2025
EXPANDED OUR DOMESTIC CVM/ TAM BY 77% DURING APR-23 TO DEC-2025 MAT Mar’22 Revenue = Rs. 1,662 cr. MAT Dec’25 Revenue = Rs. 3,004 Cr. Rest Gastro Rest WHC Critical Care Oral Anti- 8% Oral anti CNS diabetes 2% 4% 4% Nephro 3% CNS diabetes 3% 22% 8% 32% 4% WHC 5% 20% 12% VMN 15% Insulins + GLP-1 VMN 1
Slide 13: Dominant power brands; successfully leveraged LOE opportunities
DOMINANT POWER BRANDS; SUCCESSFULLY LEVERAGED LOE OPPORTUNITIES Our Top 20 Mother Brands with Market Share Successfully Leveraged LOE (Loss of Exclusivity) Opportunities MAT Dec’25 Sales (₹ Cr) Market share 333 283 2,989 4% Vildagliptin – Launched Dec-19 169170 1,713 9% Rank #2 among BGx 158 1,566 1
Slide 14: Established player in anti-diabetes with full-spectrum presence
ESTABLISHED PLAYER IN ANTI-DIABETES WITH A FULL-SPECTRUM PRESENCE Eris ranks in Anti-Diabetes therapy Eris market share in Anti-Diabetes* By Revenue* By # Rx 6.0% 4.9% 5 6 Mar'23 Dec'25 • The only 19-year old company to have achieved a Top-5 market rank in Anti-Diabetes • And the only company with a
Slide 15: RHI cartridges – tripled market share since acquisition
RHI CARTRIDGES – TRIPLED MARKET SHARE SINCE ACQUISITION RHI Cartridges – Eris market share by Rx RHI Cartridges – Eris market share by Sales + 1,800 bps 28% + 1,700 bps 25% Our stated objective of 25% 23% market share in 15% Insulins at the time of Biocon 10% 8% acquisition • Achieved in RHI Carts s
Slide 16: Overall insulins market – reaffirming our right to win
OVERALL INSULINS MARKET – REAFFIRMING OUR RIGHT TO WIN Total RHI + Glargine – Eris Market Shares Insulin Analogues Product Market Size + 700 bps 16% Aspart and Aspart Mix Rs. 650+ cr. Our Insulins Strategy 13% Degludec & comb. Rs. 800 cr. 25% market share 9% Lispro Rs. 300+ cr. in our core RHI + Tot
Slide 17: Insulin manufacturing at Bhopal – on course despite delays
INSULIN MANUFACTURING AT BHOPAL – ON COURSE DESPITE DELAYS Product Segment Status of in-house manufacturing RHI Vials Started in Aug-25; manufactured over 5 million vials since Glargine Vials Initiated in Feb 2026 Process Validation batches in Q4-FY26 Cartridges (RHI + Glargine) Commercial manufactu
Slide 18: GLP-1 update – launch readiness and manufacturing self-sufficiency
GLP-1 UPDATE – LAUNCH READINESS AND MANUFACTURING SELF-SUFFICIENCY Exciting Market Opportunity Go-to-Market Readiness ▪ Large and fast-emerging GLP-1 market in India ▪ Strategic partnership announced with Natco Pharma Ltd for launch of Semaglutide injection in ▪ Endocrinologists/ Diabetologists cont
Slide 19: India-centric studies focused on improving disease management
INDIA-CENTRIC STUDIES FOCUSED ON IMPROVING DISEASE MANAGEMENT India Head and Neck Cancer Study About the Study About the Study About the Study Long Term Results Of A Randomized Cardiovascular risk in newly diagnosed One of its kind study on Hypertension Phase III Study Of Nimotuzumab T2DM patients i
Slide 20: Patient care initiative – a differentiated service platform
PATIENT CARE INITIATIVE – A DIFFERENTIATED SERVICE PLATFORM Key elements of Eris Patient Care Platform ▪ Objective - Bring cutting- edge healthcare solutions to patients through the involvement of Key Opinion Leaders ▪ State-of-the-art diagnosis at home, followed by customised treatment plans ▪ Help
Slide 21: R&D, Technology & Manufacturing
• Introduction • Domestic Branded Formulations • R&D, Technology & Manufacturing • International Business 20
Slide 22: State-of-the-art R&D centre with a wide range of dosage capabilities
STATE-OF-THE-ART R&D CENTRE WITH A WIDE RANGE OF DOSAGE CAPABILITIES R&D Facility is situated in our Unit-3 Campus, which is a 15- Formulation Development Capabilities minute commute from our sterile facilities (Unit-1 and Unit-2) Dedicated Production Lines for various dosage forms: ✓ State-of-the-a
Slide 23: Our diabesity product pipeline spanning insulin analogs and GLP-1
OUR DIABESITY PRODUCT PIPELINE SPANNING INSULIN ANALOGS AND GLP-1 Candidate H1-F26 H2-F26 H1-F27 H2-F27 H1-F28 H2-F28 Insulin Analogues ~ Rs. 1,700+ cr. p.a. market with 3-year CAGR of 11% - presently dominated by Innovator Aspart Aspart Mix Form. Dev. Ph-I trial Phase-III trial Degludec Preclinical
Slide 24: Building momentum in our small molecule pipeline
BUILDING MOMENTUM IN OUR SMALL MOLECULE PIPELINE OF INNOVATIVE FDCs* AND FIRST-TO-MARKET PRODUCTS FY23 FY24 FY25 FY26 Start of Year 3 7 14 0 pipeline Additions 5 8 10 15 during the year Launches 2 4 3 11 (Planned) in the year Pipeline entering 7 14 18 (for FY27) 3 next year A modest beginning in FY2
Slide 25: Six manufacturing units across a wide range of tech/dosage forms
SIX MANUFACTURING UNITS ACROSS A WIDE RANGE OF TECH/ DOSAGE FORMS AMD CAMPUS – INJECTABLES, AMD – GENERAL INJECTABLES AMD – BETALACTAM INJECTABLES DERMATOLOGY AND ORAL SOLIDS BIOLOGICS FILL-FINISH - BHOPAL BIOLOGICS BULK - CHENNAI GUWAHATI – ORAL SOLIDS 24
Slide 26: EU-GMP and ANVISA approved sterile manufacturing facilities
EU-GMP AND ANVISA APPROVED STERILE MANUFACTURING FACILITIES Unit 1 – General Injectables – Ampoules, Vials, Dry Powders, PFS, Lyophilised Dosage Form Units per month Liquid Ampoules 8 million Liquid Vials 3.6 million Dry Powder Vials 2.6 million Prefilled Syringes 1.3 million Lyophilized Vials 800,0
Slide 27: Our Bhopal biologics manufacturing facility
OUR BHOPAL BIOLOGICS MANUFACTURING FACILITY Capabilities across 4 presentations ✓ Liquid Vials ✓ Prefilled Syringes ✓ Lyophilised Vials ✓ Liquid Cartridges • Presently manufacturing Liquid and Lyophilised vials for Insulin Glargine and RHI (Recombinant Human Insulin) • Will commission cartridge manu
Slide 28: International Business
• Introduction • Domestic Branded Formulations • R&D, Technology & Manufacturing • International Business 27
Slide 29: International business – presence across 70+ world markets
INTERNATIONAL BUSINESS – PRESENCE ACROSS 70+ WORLD MARKETS Emerging • Our International presence Middle East Presence spans 70+ in the EU countries across Latin America, Pan-Africa Africa, Asia Pacific, the Middle East and CIS countries Central & Latin APac • ANVISA approval for America injectable f
Slide 30: Leveraging our manufacturing footprint to expand our global access
LEVERAGING OUR MANUFACTURING FOOTPRINT TO EXPAND OUR GLOBAL ACCESS Approved India PIC/s Anvisa EU Approvable FY23 Eris AMD * Evolving from an “India-only” business to an FY24 Swiss “India + International” FY25 Eris Bhopal business FY25 Levim 29 * Approved by Brazil (Anvisa) in Aug 2025 (oral liquid
Slide 31: Key international accreditations for our injectable facilities
KEY INTERNATIONAL ACCREDITATIONS FOR OUR INJECTABLE FACILITIES 30
Slide 32: Reminding ourselves – why did we find Swiss Parenterals attractive?
REMINDING OURSELVES – WHY DID WE FIND SWISS PARENTERALS ATTRACTIVE? Value Driver Key attributes Our thesis in Exports Pure-play injectables 60% General and 40% • We found Swiss to be the business Betalactams only RoW focused Indian pharmaco with 60%+ ROCE with a strong reputation for Marquee regulat
Slide 33: We undertook focused action to expand our capabilities
WE UNDERTOOK WE UNDERTOOK FOCUSED FOCUSED ACTION ACTION TO TO EXPAND EXPAND OUR OUR CAPABILITIES CAPABILITIES 1 2 3 R&D/ Tech. Transfer Capability Manufacturing & Quality Go-to-Market Capability • Onboarded a new Head-R&D • Secured our first Brazilian • Strengthened our customer- from a Top-10 India
Slide 34: Significant visibility on FY27 being a breakout year for the business
SIGNIFICANT VISIBLITY ON FY27 BEING A BREAKOUT YEAR FOR THE BUSINESS Key growth drivers for FY27/ beyond 1 • EU-CDMO book of business* ramping up • With a third injectable • Rs.100+ cr. at the end of Q1 unit set to be • Rs. 700-800 cr. at the end of Q2 commissioned in FY28 • Rs. 1,000+ cr. at the en
Slide 35: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 36: Thank You!
Registered Office Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat - 380054 For Further Information, Please Contact: Thank You! Kruti Raval / Atul Modi https://eris.co.in/ investor.relations@eris.co.in E: kruti@erislifesciences.com E: atul.modi@e
Slide 37: Appendix
a = V4 “2 — APPENDIX
Slide 38: Business structure and holdings
BUSINESS STRUCTURE AND HOLDINGS Eris Lifesciences Limited Shareholding Pattern as of Dec 2025 Others, 0.69% Eris Therapeutics Limited Public, 8.51% Eris Oaknet Healthcare Private Ltd (Step-down subsidiary) FPIs, 15.64% Aprica Healthcare Limited (Step-down subsidiary) Eris Healthcare Private Limited
Slide 39: Financial Summary (1/2)
FINANCIAL SUMMARY (1/2) P&L Summary FY19 FY20 FY21 FY22 FY23 FY24 FY25 Revenue 982 1,074 1,212 1,347 1,685 2,009 2,894 Gross Profit 828 903 974 1,089 1,333 1,629 2,180 Gross Profit Margin (%) 84.4% 84.0% 80.3% 80.8% 79.1% 81.1% 75.3% Operating EBITDA 345 368 431 485 537 675 1,017 Operating EBITDA Ma
Slide 40: Financial Summary (2/2)
FINANCIAL SUMMARY (2/2) FY19 FY20 FY21 FY22 FY23 FY24 FY25 BS Summary Mar'19 Mar'20 Mar'21 Mar’22 Mar’23 Mar’24 Mar’25 Margin (%) Share Capital 14 14 14 14 14 14 14 Gross Margin 84.4% 84.0% 80.3% 80.8% 79.1% 81.1% 75.3% Reserves 1,137 1,283 1,563 1,895 2,182 2,573 2,841 EBITDA Margin 35.1% 34.3% 35.
Slide 41: Thank You
THANK YOU Eris Lifesciences 40
Eris Lifesciences — Investor Presentation (February 2026) on 6ix